Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules

Journal of Pharmacology and Experimental Therapeutics

Volumn 354, Issue 1, 2015, Pages 55-64

  Mangas Sanjuan, Víctor ^a   Buil Bruna, Núria ^b   Garrido, María J ^b   Soto, Elena ^c   Trocóniz, Iñaki F ^b  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIFLOMOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ADVANCED CANCER; ARTICLE; CELL COMPARTMENTALIZATION; CELL CYCLE; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SOLID TUMOR; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BLOOD; BONE MARROW CELL; CHEMICALLY INDUCED; DRUG ADMINISTRATION; DRUG EFFECTS; NEOPLASMS; NEUTROPHIL; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); STEM CELL;

ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CAMPTOTHECIN; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEUTROPENIA; NEUTROPHILS; STEM CELLS;

EID: 84939451287     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.223776     Document Type: Article

References (26)

1. Bauer R (2011) NONMEM users guide: Introduction to NONMEM 7.2.0, ICON Development Solutions, Ellicott City, MD.
2. Bergstrand M, Hooker AC, Wallin JE, and Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13: 143-151.
3. Clairambault J and Fercoq O (2012) Physiologically structured cell population dynamic models with applications to combined drug delivery optimisation in oncology, in Mathematical Modelling of Cancer Growth and Treatment. (Bachar M, Batzel J, and Chaplain M eds) Springer, New York.
4. Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M, Kane MP, et al. (2008) Pharmacokinetic/ pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clin Cancer Res 14:5856-5863.
5. Friberg LE, Henningsson A, Maas H, Nguyen L, and Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713-4721.
6. Friberg LE, Sandström M, and Karlsson MO (2010) Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model. Invest New Drugs 28:744-753.
7. Hing J, Perez-Ruixo JJ, Stuyckens K, Soto-Matos A, Lopez-Lazaro L, and Zannikos P (2008) Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia. Clin Pharmacol Ther 83: 130-143.
8. Jonsson EN and Karlsson MO (1999) Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51-64.
9. Krzyzanski W and Jusko WJ (2002) Multiple-pool cell lifespan model of hematologic effects of anticancer agents. J Pharmacokinet Pharmacodyn 29:311-337.
10. Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, and Johnson RD (2006) A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57:412-426.
11. Léger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, Verweij J, Sparreboom A, and Chatelut E (2004) Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther 76:567-578.
12. Lindbom L, Pihlgren P, and Jonsson EN (2005) PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NON-MEM. Comput Methods Programs Biomed 79:241-257.
13. Minami H, Sasaki Y, Saijo N, Ohtsu T, Fujii H, Igarashi T, and Itoh K (1998) Indirect-response model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Ther 64:511-521.
14. Panetta JC, Kirstein MN, Gajjar AJ, Nair G, Fouladi M, and Stewart CF (2003) A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. Math Biosci 186:29-41.
15. Panetta JC, Schaiquevich P, Santana VM, and Stewart CF (2008) Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin Cancer Res 14:318-325.
16. Pietras EM, Warr MR, and Passegué E (2011) Cell cycle regulation in hematopoietic stem cells. J Cell Biol 195:709-720.
17. Quesenberry PJ, Goldberg LR, and Dooner MS (2015) Concise reviews: A stem cell apostasy: a tale of four H words. Stem Cells 33:15-20.
18. Reddy GP, Tiarks CY, Pang L, Wuu J, Hsieh CC, and Quesenberry PJ (1997) Cell cycle analysis and synchronization of pluripotent hematopoietic progenitor stem cells. Blood 90:2293-2299.
19. Sandström M, Lindman H, Nygren P, Lidbrink E, Bergh J, and Karlsson MO (2005) Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 23:413-421.
20. Schoemaker RC, van Gerven JM, and Cohen AF (1998) Estimating potency for the Emax-model without attaining maximal effects. J Pharmacokinet Biopharm 26: 581-593.
21. Soto E, Keizer RJ, Trocóniz IF, Huitema AD, Beijnen JH, Schellens JH, Wanders J, Cendrós JM, Obach R, Peraire C, et al. (2011) Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. Invest New Drugs 29:984-995.
22. Soto E, Staab A, Freiwald M, Munzert G, Fritsch H, Döge C, and Trocóniz IF (2010a) Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed. Clin Pharmacol Ther 88:660-667.
23. Soto E, Staab A, Tillmann C, Trommeshauser D, Fritsch H, Munzert G, and Trocóniz IF (2010b) Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development. Cancer Chemother Pharmacol 66:785-795.
24. Steimer JL, Dahl SG, De Alwis DP, Gundert-Remy U, Karlsson MO, Martinkova J, Aarons L, Ahr HJ, Clairambault J, Freyer G, et al. (2010) Modelling the genesis and treatment of cancer: the potential role of physiologically based pharmacodynamics. Eur J Cancer 46:21-32.
25. Trocòniz IF, Garrido MJ, Segura C, Cendrós JM, Principe P, Peraire C, and Obach R (2006) Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer Chemother Pharmacol 57:727-735.
26. Zamboni WC, D'Argenio DZ, Stewart CF, MacVittie T, Delauter BJ, Farese AM, Potter DM, Kubat NM, Tubergen D, and Egorin MJ (2001) Pharmacodynamic model of topotecan-induced time course of neutropenia. Clin Cancer Res 7: 2301-2308.